Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis.

Arthritis Rheumatol · 2026 · PMC13129633 · PMID 41327832

Europe PMC DOI

hedged sentences

0.0740

closest p · 1.5× alpha

0.0740

boldest claim

The sentences

a trend toward significanceP = 0.074so close (0.05 < p ≤ 0.1)

Group comparisons In the MMRM, we found a trend toward significance at lumbar spine M+12 between the Dmab + Romo and Dmab‐alone groups (difference between groups 3.2%, 95% CI −5.4 to 11.8; P = 0.074).

also in 2,517 other papers

did not reach statistical significanceno p-value reported

Dmab‐alone continued BMD slightly increased at all sites between M0 and M+12 but did not reach statistical significance at any site.

also in 75,868 other papers

a nonsignificant trendno p-value reported

The between‐group difference at M+12 was 3.3% (95% confidence interval −5.2 to 11.8), indicating a nonsignificant trend toward greater improvement with combination therapy.

also in 3,472 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.